On March 11, 2017, the first pair of participants completed their six-month follow-up interview in our new study of MDMA combined with Cognitive Behavioral Conjoint Therapy (CBCT) for PTSD in our Charleston, South Carolina site led by Principal Investigator, Michael Mithoefer, M.D., and Sub-Investigator, Candice Monson, Ph.D. The study will enroll 10 dyads, with one participant diagnosed with PTSD and one concerned significant other who does not have PTSD but does experience psychosocial distress. Three dyads have completed treatment so far. The primary goal of this study is to develop a combined method of MDMA with CBCT for PTSD. MDMA will be administered to both participants to help facilitate communication and connection between participants and therapists. Learn more…
